These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 22001462)

  • 1. Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension.
    Shimizu M; Imanishi J; Takano T; Miwa Y
    Intern Med; 2011; 50(20):2341-6. PubMed ID: 22001462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new era in the treatment of primary pulmonary hypertension.
    Bailey CL; Channick RN; Rubin LJ
    Heart; 2001 Mar; 85(3):251-2. PubMed ID: 11179256
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
    Brancaccio G; Toscano A; Bevilacqua M; Di Chiara L; Parisi F
    Pediatr Transplant; 2007 Feb; 11(1):110-2. PubMed ID: 17239133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.
    Hoeper MM; Taha N; Bekjarova A; Gatzke R; Spiekerkoetter E
    Eur Respir J; 2003 Aug; 22(2):330-4. PubMed ID: 12952269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan for the treatment of portopulmonary hypertension.
    Tempe DK; Datt V; Datta D
    Ann Card Anaesth; 2008; 11(2):139-40; author reply 140. PubMed ID: 18603763
    [No Abstract]   [Full Text] [Related]  

  • 7. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
    Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Report from the 93rd Cardiovascular and Renal Drugs Advisory Committee Meeting, August 9-10, 2001.
    Fleming T; Lindenfeld J; Lipicky R; Armstrong P
    Circulation; 2001 Oct; 104(15):1742. PubMed ID: 11591605
    [No Abstract]   [Full Text] [Related]  

  • 9. Pulmonary arterial hypertension: combination therapy in the modern management era.
    Sitbon O
    Eur Respir Rev; 2010 Dec; 19(118):348-9. PubMed ID: 21119195
    [No Abstract]   [Full Text] [Related]  

  • 10. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
    Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
    Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
    Hall SM; Davie N; Klein N; Haworth SG
    Eur Respir J; 2011 Oct; 38(4):851-60. PubMed ID: 21406517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
    Demerouti EA; Manginas AN; Athanassopoulos GD; Karatasakis GT; Leontiadis ED; Pavlides GS
    Respir Care; 2013 Feb; 58(2):e1-5. PubMed ID: 22710078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapy for pulmonary arterial hypertension: what's on the menu today?
    Mehta S
    Chest; 2003 Dec; 124(6):2045-9. PubMed ID: 14665473
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
    Jacobs W; Boonstra A; Brand M; Rosenberg DM; Schaaf B; Postmus PE; Vonk Noordegraaf A
    J Heart Lung Transplant; 2010 Oct; 29(10):1150-8. PubMed ID: 20580264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the treatment of secondary pulmonary hypertension.
    Maloney JP
    Curr Opin Pulm Med; 2003 Mar; 9(2):139-43. PubMed ID: 12574694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
    Humbert M; Barst RJ; Robbins IM; Channick RN; Galiè N; Boonstra A; Rubin LJ; Horn EM; Manes A; Simonneau G
    Eur Respir J; 2004 Sep; 24(3):353-9. PubMed ID: 15358690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusion.
    Prescrire Int; 2005 Apr; 14(76):47-50. PubMed ID: 15875338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
    Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS
    Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.